Shopping Cart
- Remove All
- Your shopping cart is currently empty
Voreloxin (SNS-595) is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 116 € | 35 days | |
5 mg | 370 € | 35 days | |
25 mg | 1.406 € | 35 days |
Description | Voreloxin (SNS-595) is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2. |
In vitro | Suprofen inactivates the diclofenac-4-hydroxylase activity of baculovirus-expressed P450 2C9 in a time- and concentration-dependent manner, which is consistent with mechanism-based inactivation. [1] Suprofen is a known generator of singlet oxygen whose participation in the reaction is supported by the effects of quenchers and scavengers. Suprofen photosensitizes the production of alkali-labile cleavage sites in DNA much more efficiently than direct strand breaks. [2] Suprofen sensitizes photo-oxidation of cholesterol, producing 7 alpha- and 7 beta-hydroperoxides but not 5 alpha-hydroperoxide of cholesterol. Suprofen-sensitized photo-oxidation of membrane lipids of liposomes increases leakage of trapped glucose, suggesting photosensitized destabilization of the membrane structure. [3] Suprofen incorporation in the phosphatidylcholine (PC) evaporation vesicles (REV) membrane leads to approximately 5% increase in the encapsulation efficiency (34%) in comparison to standard REV (29%). [4] |
Alias | Vosaroxin, SNS-595, AG 7352 |
Molecular Weight | 401.44 |
Formula | C18H19N5O4S |
Cas No. | 175414-77-4 |
Relative Density. | 1.52 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 20 mg/mL (49.82 mM), Heating is recommended. H2O: <1 mg/mL Ethanol: <1 mg/mL | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.